Literature DB >> 30681431

Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series.

Kayla Balaj1, Lisa Nowinski2,3, Brianna Walsh2, Jennifer Mullett2, Michelle L Palumbo2,3, Ronald L Thibert2,3,4, Christopher J McDougle2,3,4, Christopher J Keary2,3,4.   

Abstract

OBJECTIVES: Angelman syndrome (AS) is a neurogenetic disorder associated with impaired expression of the ubiquitin-protein ligase E3A gene on chromosome 15. AS results in intellectual disability with limited expressive language, epilepsy, ataxia, sleep impairment, and problematic behavior which may include anxiety. Buspirone is a serotonin (5-HT)1A receptor partial agonist used in the treatment of anxiety disorders and may, therefore, have a treatment role for patients with AS.
METHODS: We describe three patients who were given open-label buspirone for the treatment of behaviors thought to be related to anxiety.
RESULTS: We found significant improvement in symptoms of anxiety with buspirone. Patients tolerated long-term usage of the medication.
CONCLUSION: The findings of this study suggest that buspirone may be effective for the amelioration of behaviors related to anxiety in patients with AS, and well tolerated. Limitations include the open-label nature of these treatments, the small sample size and the absence of a control group.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30681431     DOI: 10.1097/YPG.0000000000000218

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  3 in total

1.  Mirtazapine for sleep disturbances in Angelman syndrome: a retrospective chart review of 8 pediatric cases.

Authors:  Emily Hanzlik; Sarah A Klinger; Robert Carson; Jessica Duis
Journal:  J Clin Sleep Med       Date:  2020-04-15       Impact factor: 4.062

Review 2.  Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.

Authors:  Gabrielle E Hodgins; Kristen Winsor; Jarrett Barnhill
Journal:  Paediatr Drugs       Date:  2022-07-04       Impact factor: 3.930

Review 3.  Serotonin receptors in epilepsy: Novel treatment targets?

Authors:  Jo Sourbron; Lieven Lagae
Journal:  Epilepsia Open       Date:  2022-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.